Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T18:53:35.587Z.
Calculation as of: 2026-10-06T18:53:35.587Z.
Quote observation: 2026-10-06T18:50:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc4657557541446f84d9f7820ae4f915e84790dbce56ed6e08d87a0074ca8553
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Viking Therapeutics, Inc.
Market Cap
$3.32B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.33B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.36B
Operating Cash Flow Yield
2.79%
TTM Avg
4.26%
3Y Avg
3.12%
5Y Avg
2.89%
Market Cap
$3.38B
Operating Cash Flow Yield
5.74%
TTM Avg
3.90%
3Y Avg
3.98%
5Y Avg
3.98%
Market Cap
$3.21B
Operating Cash Flow Yield
2.49%
TTM Avg
2.45%
3Y Avg
2.45%
5Y Avg
1.16%
Market Cap
$3.44B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.49B
Operating Cash Flow Yield
N/A
TTM Avg
9.25%
3Y Avg
9.27%
5Y Avg
9.27%
Market Cap
$3.51B
Operating Cash Flow Yield
N/A
TTM Avg
0.18%
3Y Avg
0.18%
5Y Avg
0.18%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | $3.32B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.36B | 2.79% | 4.26% | 3.12% | 2.89% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 5.74% | 3.90% | 3.98% | 3.98% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.21B | 2.49% | 2.45% | 2.45% | 1.16% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | N/A | 9.25% | 9.27% | 9.27% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.51B | N/A | 0.18% | 0.18% | 0.18% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.53B | N/A | 6.86% | 6.86% | 6.86% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
